Literature DB >> 7499004

Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.

S G Jenkins1, J W Lewis.   

Abstract

Antimicrobial synergy resulting from combined antibiotic therapy is often important in the treatment of serious bacterial infections. To investigate the interactions between cefotaxime (CTX), desacetylcefotaxime (DES), and ofloxacin (OFL), 247 recent clinical isolates were tested for in vitro susceptibility to each antibiotic alone by an agar dilution technique and retested with the various antibiotic combinations using a checkerboard protocol. Fractional inhibitory concentrations were calculated for all organisms with all drug combinations. Time kill kinetic studies were performed on selected isolates to examine the bactericidal activity of the various antimicrobial combinations. Of the 110 gram-negative organisms tested, synergy or partial synergy between CTX, DES and OFL was demonstrable for 89 (81%). Included in the study were 70 members of the Enterobacteriaceae family, 20 isolates of Pseudomonas aeruginosa, 10 strains of Acinetobacter baumannii, and 10 isolates of Xanthomonas maltophilia. Additive activity was observed against an additional 13 (11%) isolates. Findings were similar for the 89 gram-positive isolates examined. Organisms tested included methicillin-resistant Staphylococcus aureus (20), methicillin-susceptible Staphylococcus aureus (20), methicillin-resistant Staphylococcus epidermidis (9), methicillin-susceptible S. epidermidis (10), Enterococcus faecalis (10), and Streptococcus pneumoniae (20). Synergy or partial synergy was observed against 81 (91%). Less synergistic activity was detected, however, with members of the Bacteroides fragilis group. Of the 48 organisms tested, synergy or partial synergy was noted for only 27 (57%). Isolates representative of each major group of organisms included in the study were tested to determine whether synergistic bactericidal activity was also demonstrable with the three drugs. Time kill studies supported the checkerboard results.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499004     DOI: 10.1007/bf01793856

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

Review 1.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

2.  Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.

Authors:  S G Jenkins
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

3.  Decimal assay for additivity of drugs permits delineation of synergy and antagonism.

Authors:  C C Sanders; W E Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.

Authors:  L B Reller
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

5.  Comparative pharmacokinetics of cefotaxime and ceftizoxime and the role of desacetylcefotaxime in the antibacterial activity of cefotaxime.

Authors:  R Quintiliani; C H Nightingale; R Tilton
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

6.  In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.

Authors:  K E Aldridge; C V Sanders; R L Marier
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

7.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

8.  Fleroxacin combined with rifampin.

Authors:  Y X Zhang; H C Neu
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

9.  Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations.

Authors:  A G Maiche; L Teerenhovi
Journal:  Infection       Date:  1991       Impact factor: 3.553

10.  The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.

Authors:  M Limbert; G Seibert; E Schrinner
Journal:  Infection       Date:  1982       Impact factor: 3.553

View more
  4 in total

1.  Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.

Authors:  D E Nix; J H Wilton; J Hyatt; J Thomas; L C Strenkoski-Nix; A Forrest; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 2.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 3.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Epidemiology and antimicrobial resistance of staphylococci isolated from different infectious diseases.

Authors:  Gamal Fadl M Gad; Abd El-Ghafar; Ramadan A A El-Domany; Zeinab Shawky Hashem
Journal:  Braz J Microbiol       Date:  2010-06-01       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.